- Home
- CRBP vs NVNI Comparison
CRBP vs NVNI Comparison
Compare CRBP & NVNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- NVNI
- Stock Information
- Founded
- CRBP 2009
- NVNI 2019
- Country
- CRBP United States
- NVNI Brazil
- Employees
- CRBP N/A
- NVNI N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- NVNI
- Sector
- CRBP Health Care
- NVNI
- Exchange
- CRBP Nasdaq
- NVNI Nasdaq
- Market Cap
- CRBP 103.6M
- NVNI 99.0M
- IPO Year
- CRBP N/A
- NVNI N/A
- Fundamental
- Price
- CRBP $8.18
- NVNI $2.51
- Analyst Decision
- CRBP Strong Buy
- NVNI
- Analyst Count
- CRBP 8
- NVNI 0
- Target Price
- CRBP $61.38
- NVNI N/A
- AVG Volume (30 Days)
- CRBP 291.7K
- NVNI 22.8M
- Earning Date
- CRBP 03-11-2025
- NVNI 03-04-2025
- Dividend Yield
- CRBP N/A
- NVNI N/A
- EPS Growth
- CRBP N/A
- NVNI N/A
- EPS
- CRBP N/A
- NVNI N/A
- Revenue
- CRBP N/A
- NVNI $23,558,620.00
- Revenue This Year
- CRBP N/A
- NVNI $25.91
- Revenue Next Year
- CRBP N/A
- NVNI $17.52
- P/E Ratio
- CRBP N/A
- NVNI N/A
- Revenue Growth
- CRBP N/A
- NVNI 38.59
- 52 Week Low
- CRBP $7.64
- NVNI $0.33
- 52 Week High
- CRBP $61.90
- NVNI $12.19
- Technical
- Relative Strength Index (RSI)
- CRBP 35.10
- NVNI 41.36
- Support Level
- CRBP $7.64
- NVNI $2.26
- Resistance Level
- CRBP $9.51
- NVNI $7.58
- Average True Range (ATR)
- CRBP 0.84
- NVNI 0.92
- MACD
- CRBP -0.05
- NVNI -0.36
- Stochastic Oscillator
- CRBP 13.71
- NVNI 4.79
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.